Table 4.

Cytotoxicities and Anti-HIV-1 activities of curcumin bioconjugates 2, 3, 6, 8 and 10.

Compound	HIV-1 Strains	Exp_nr	IC50a	CC50b	SIc
2	IIIB	P3.4401	>0.094	=0.094	<1
		P3.4406	>0.093	=0.093	<1
	ROD	P3.4402	>0.107	=0.107	<1
		P3.4407	>0.103	=0.103	<1
3	IIIB	P3.4401	>0.081	=0.081	<1
		P3.4406	>0.091	=0.091	<1
	ROD	P3.4402	>0.079	=0.079	<1
		P3.4407	>0.044	=0.044
6	IIIB	P3.4401	>0.036	=0.036	<1
		P3.4406	>0.046	=0.046
	ROD	P3.4402	>0.046	=0.046	<1
		P3.4407	>0.050	=0.050
8	IIIB	P3.4401	>0.063	=0.063	<1
		P3.4406	>0.063	=0.063
	ROD	P3.4402	>0.065	=0.065	<1
		P3.4407	>0.062	=0.062
10	IIIB	P3.4401	>0.063	=0.063	<1
		P3.4406	>0.058	=0.058
	ROD	P3.4402	>0.069	=0.069	<1
		P3.4407	>0.088	=0.088
Curcumin	IIIB	P3.4401	>0.037	=0.037	<1
		P3.4406	>0.034	=0.034
	ROD	P3.4402	>0.037	=0.037	<1
		P3.4407	>0.039	=0.039

^aCompound concentration (μM) required to reduce the viability of mock-infected cells by 50% as determined by MTT method.

^bCompound concentration (μM) required to achieve 50% protection of MT-4 cells from HIV-1-induced cytopathogenicity as determined by MTT method.

^cSelectivity index: CC₅₀/IC₅₀ ratio.